HER-2 underexpression

News alerts, weekly reports and conference planners

Entrez ID:

2064

Related biomarkers:

‹

›

HER-2 underexpression	Breast Cancer	HER-2 underexpression	Breast Cancer	eribulin mesylate Sensitive: B - Late Trials SABCS 2022 - 1 week (New B) eribulin mesylate Sensitive : B SABCS 2022 - 1wk	eribulin mesylate Sensitive: B - Late Trials SABCS 2022 - 1 week eribulin mesylate Sensitive : B SABCS 2022 - 1 week - (New B)
HER-2 underexpression	Breast Cancer	HER-2 underexpression	Breast Cancer	disitamab vedotin + ABBV-IMAB-TJC4 Sensitive: D – Preclinical SITC 2022 - 3 weeks (New D) disitamab vedotin + ABBV-IMAB-TJC4 Sensitive : D SITC 2022 - 3wk	disitamab vedotin + ABBV-IMAB-TJC4 Sensitive: D – Preclinical SITC 2022 - 3 weeks disitamab vedotin + ABBV-IMAB-TJC4 Sensitive : D SITC 2022 - 3 weeks - (New D)
HER-2 underexpression	Breast Cancer	HER-2 underexpression	Breast Cancer	trastuzumab-pkrb Sensitive: D – Preclinical SITC 2022 - 3 weeks (New D) trastuzumab-pkrb Sensitive : D SITC 2022 - 3wk	trastuzumab-pkrb Sensitive: D – Preclinical SITC 2022 - 3 weeks trastuzumab-pkrb Sensitive : D SITC 2022 - 3 weeks - (New D)
HER-2 underexpression	Breast Cancer	HER-2 underexpression	Breast Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval fam-trastuzumab deruxtecan-nxki Sensitive : A1	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval fam-trastuzumab deruxtecan-nxki Sensitive : A1
HER-2 underexpression	Hormone Receptor Positive Breast Cancer	HER-2 underexpression	Hormone Receptor Positive Breast Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: B - Late Trials fam-trastuzumab deruxtecan-nxki Sensitive : B	fam-trastuzumab deruxtecan-nxki Sensitive: B - Late Trials fam-trastuzumab deruxtecan-nxki Sensitive : B
HER-2 underexpression	Gastroesophageal Junction Adenocarcinoma	HER-2 underexpression	Gastroesophageal Junction Adenocarcinoma	fam-trastuzumab deruxtecan-nxki Sensitive: C1 - Off-label fam-trastuzumab deruxtecan-nxki Sensitive : C1	fam-trastuzumab deruxtecan-nxki Sensitive: C1 - Off-label fam-trastuzumab deruxtecan-nxki Sensitive : C1
HER-2 underexpression	Gastric Cancer	HER-2 underexpression	Gastric Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: C1 - Off-label fam-trastuzumab deruxtecan-nxki Sensitive : C1	fam-trastuzumab deruxtecan-nxki Sensitive: C1 - Off-label fam-trastuzumab deruxtecan-nxki Sensitive : C1
HER-2 underexpression	Triple Negative Breast Cancer	HER-2 underexpression	Triple Negative Breast Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: C1 - Off-label fam-trastuzumab deruxtecan-nxki Sensitive : C1	fam-trastuzumab deruxtecan-nxki Sensitive: C1 - Off-label fam-trastuzumab deruxtecan-nxki Sensitive : C1
HER-2 underexpression	Breast Cancer	HER-2 underexpression	Breast Cancer	ado-trastuzumab emtansine Sensitive: C2 – Inclusion Criteria ado-trastuzumab emtansine Sensitive : C2	ado-trastuzumab emtansine Sensitive: C2 – Inclusion Criteria ado-trastuzumab emtansine Sensitive : C2
HER-2 underexpression	Solid Tumor	HER-2 underexpression	Solid Tumor	IKS014 Sensitive: C2 – Inclusion Criteria IKS014 Sensitive : C2	IKS014 Sensitive: C2 – Inclusion Criteria IKS014 Sensitive : C2
HER-2 underexpression	Solid Tumor	HER-2 underexpression	Solid Tumor	KN046 + KN026 Sensitive: C3 – Early Trials KN046 + KN026 Sensitive : C3	KN046 + KN026 Sensitive: C3 – Early Trials KN046 + KN026 Sensitive : C3
HER-2 underexpression	Lung Adenocarcinoma	HER-2 underexpression	Lung Adenocarcinoma	ado-trastuzumab emtansine Sensitive: C3 – Early Trials ado-trastuzumab emtansine Sensitive : C3	ado-trastuzumab emtansine Sensitive: C3 – Early Trials ado-trastuzumab emtansine Sensitive : C3
HER-2 underexpression	Breast Cancer	HER-2 underexpression	Breast Cancer	SYD985 Sensitive: C3 – Early Trials SYD985 Sensitive : C3	SYD985 Sensitive: C3 – Early Trials SYD985 Sensitive : C3
HER-2 underexpression	Hormone Receptor Positive Breast Cancer	HER-2 underexpression	Hormone Receptor Positive Breast Cancer	SYD985 Sensitive: C3 – Early Trials SYD985 Sensitive : C3	SYD985 Sensitive: C3 – Early Trials SYD985 Sensitive : C3
HER-2 underexpression	Breast Cancer	HER-2 underexpression	Breast Cancer	MRG002 Sensitive: C3 – Early Trials MRG002 Sensitive : C3	MRG002 Sensitive: C3 – Early Trials MRG002 Sensitive : C3
HER-2 underexpression	Ovarian Cancer	HER-2 underexpression	Ovarian Cancer	olaparib + niraparib + SYD985 Sensitive: D – Preclinical olaparib + niraparib + SYD985 Sensitive : D	olaparib + niraparib + SYD985 Sensitive: D – Preclinical olaparib + niraparib + SYD985 Sensitive : D
HER-2 underexpression	Colorectal Cancer	HER-2 underexpression	Colorectal Cancer	SAR446309 Sensitive: D – Preclinical SAR446309 Sensitive : D	SAR446309 Sensitive: D – Preclinical SAR446309 Sensitive : D
HER-2 underexpression	Breast Cancer	HER-2 underexpression	Breast Cancer	SAR443216 Sensitive: D – Preclinical SAR443216 Sensitive : D	SAR443216 Sensitive: D – Preclinical SAR443216 Sensitive : D
HER-2 underexpression	Breast Cancer	HER-2 underexpression	Breast Cancer	XMT-2056 Sensitive: D – Preclinical XMT-2056 Sensitive : D	XMT-2056 Sensitive: D – Preclinical XMT-2056 Sensitive : D
HER-2 underexpression	Gastric Cancer	HER-2 underexpression	Gastric Cancer	XMT-2056 Sensitive: D – Preclinical XMT-2056 Sensitive : D	XMT-2056 Sensitive: D – Preclinical XMT-2056 Sensitive : D

HER-2 underexpression

Associations